more

Bausch Health (BHC)

(Real Time Quote from BATS)

$8.54 USD

+0.01 (0.12%)

Updated Apr 24, 2024 03:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

Bottom 36% (162 out of 252)

Industry: Medical - Generic Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on August 01,2022

In the latest trading session, Bausch Health (BHC) closed at $4.59, marking a -0.65% move from the previous day.

BHCPositive Net Change

Bausch (BHC) Loses 39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research Published on July 29,2022

The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BHCPositive Net Change

Bausch (BHC) Suspends IPO Plans for Solta Medical

by Zacks Equity Research Published on June 17,2022

Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

pharmaceuticals

Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?

by Zacks Equity Research Published on June 09,2022

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Bausch (BHC) Stock Options

by Zacks Equity Research Published on June 06,2022

Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.

BHCPositive Net Change

medical

New Strong Sell Stocks for May 19th

by Zacks Equity Research Published on May 19,2022

ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.

Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down

by Zacks Equity Research Published on May 10,2022

Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

by Kanishka Das Published on May 09,2022

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

medical

BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on May 05,2022

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on May 02,2022

Bausch Health (BHC) closed the most recent trading day at $18.85, moving -0.84% from the previous trading session.

BHCPositive Net Change

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

by Indrajit Bandyopadhyay Published on May 02,2022

The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on April 25,2022

Bausch Health (BHC) closed at $21.48 in the latest trading session, marking a -0.88% move from the prior day.

BHCPositive Net Change

Aerie (AERI) Expands Market Presence Despite Stiff Competition

by Zacks Equity Research Published on April 11,2022

Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.